Diagnostics & Research · South San Francisco, California, United States
$57.09
-3.41% (-$2.02)2026-07-10
Smart-Money SignalNeutral · 43/100— Insiders are net sellers over 90 days (-$5.6M, 20 sales vs 3 buys)
Revenue$139.1M
Net Income$28.7M
EPS$0.35
Gross Margin72.7%
Market Cap$4.6B
Price Performance
Historical data including institutional events
Company Profile
M
Marc Stapley
CEO & Executive Director
Veracyte, Inc. operates as a diagnostics company in the United States and internationally.
The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis.
It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008.
Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.